Amicus Therapeutics (FOLD) Misses Q1 EPS by 4c

Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.18), $0.04 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $86.3 million versus the consensus estimate of $83.07 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• General Mills (GIS) PT Lowered to $42 at Freedom Broker